LABELS · bd867ca4-faaf-4920-af55-ee0db99ab1bf

Olumiant

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-06-30
Captured: 2026-09-09T23:37:58.719708+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS See full prescribing information for complete boxed warning. Increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Interrupt treatment with OLUMIANT if serious infection occurs until the infection is controlled. OLUMIANT should not be given to patients with active tuberculosis. Test for latent TB before and during therapy, except for COVID-19; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test. ( 5.1 ) Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. ( 5.2 ) Malignancies have occurred in patients treated with OLUMIANT. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs. TNF blockers in RA patients. ( 5.3 ) Higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients. ( 5.4 ) Thrombosis has occurred in patients treated with OLUMIANT. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers. ( 5.5 ) SERIOUS INFECTIONS Patients treated with OLUMIANT are at risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] . Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt OLUMIANT until the infection is controlled. Reported infections include: Active tuberculosis, which may present with pulmonary or extrapulmonary disease. OLUMIANT should not be given to patients with active tuberculosis. Patients, except those with COVID-19, should be tested for latent tuberculosis before initiating OLUMIANT and during therapy. If positive, start treatment for latent infection prior to OLUMIANT use. Invasive fungal infections, including candidiasis and pneumocystosis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease. Bacterial, viral, and other infections due to opportunistic pathogens. The risks and benefits of treatment with OLUMIANT should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with OLUMIANT including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy [see Warnings and Precautions ( 5.1 )]. MORTALITY In a large, randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor [see Warnings and Precautions ( 5.2 )]. MALIGNANCIES Lymphoma and other malignancies have been observed in patients treated with OLUMIANT. In RA patients treated with another JAK inhibitor, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions ( 5.3 )]. MAJOR ADVERSE CARDIOVASCULAR EVENTS In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk. Discontinue OLUMIANT in patients that have experienced a myocardial infarction or stroke [see Warnings and Precautions ( 5.4 )]. THROMBOSIS Thrombosis, including deep venous thrombosis and pulmonary embolism, has been observed at an increased incidence in patients treated with OLUMIANT compared to placebo. In addition, there were cases of arterial thrombosis. Many of these adverse events were serious and some resulted in death. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of thrombosis was observed when compared with TNF blockers. Avoid OLUMIANT in patients at risk. Patients with symptoms of thrombosis should discontinue OLUMIANT and be promptly evaluated. [see Warnings and Precautions ( 5.5 )].

Indications and usage: exact source text

1 INDICATIONS AND USAGE OLUMIANT ® is a Janus kinase (JAK) inhibitor indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. ( 1.2 ) the treatment of adult patients with severe alopecia areata. ( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1.3 ) 1.1 Rheumatoid Arthritis OLUMIANT ® (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine. 1.2 Coronavirus Disease 2019 (COVID-19) OLUMIANT is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 1.3 Alopecia Areata OLUMIANT is indicated for the treatment of adult patients with severe alopecia areata. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.

Full extracted label fields

application numbers

NDA207924

boxed warning exact

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS See full prescribing information for complete boxed warning. Increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Interrupt treatment with OLUMIANT if serious infection occurs until the infection is controlled. OLUMIANT should not be given to patients with active tuberculosis. Test for latent TB before and during therapy, except for COVID-19; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test. ( 5.1 ) Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. ( 5.2 ) Malignancies have occurred in patients treated with OLUMIANT. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs. TNF blockers in RA patients. ( 5.3 ) Higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients. ( 5.4 ) Thrombosis has occurred in patients treated with OLUMIANT. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers. ( 5.5 ) SERIOUS INFECTIONS Patients treated with OLUMIANT are at risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] . Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt OLUMIANT until the infection is controlled. Reported infections include: Active tuberculosis, which may present with pulmonary or extrapulmonary disease. OLUMIANT should not be given to patients with active tuberculosis. Patients, except those with COVID-19, should be tested for latent tuberculosis before initiating OLUMIANT and during therapy. If positive, start treatment for latent infection prior to OLUMIANT use. Invasive fungal infections, including candidiasis and pneumocystosis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease. Bacterial, viral, and other infections due to opportunistic pathogens. The risks and benefits of treatment with OLUMIANT should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with OLUMIANT including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy [see Warnings and Precautions ( 5.1 )]. MORTALITY In a large, randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor [see Warnings and Precautions ( 5.2 )]. MALIGNANCIES Lymphoma and other malignancies have been observed in patients treated with OLUMIANT. In RA patients treated with another JAK inhibitor, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions ( 5.3 )]. MAJOR ADVERSE CARDIOVASCULAR EVENTS In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk. Discontinue OLUMIANT in patients that have experienced a myocardial infarction or stroke [see Warnings and Precautions ( 5.4 )]. THROMBOSIS Thrombosis, including deep venous thrombosis and pulmonary embolism, has been observed at an increased incidence in patients treated with OLUMIANT compared to placebo. In addition, there were cases of arterial thrombosis. Many of these adverse events were serious and some resulted in death. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of thrombosis was observed when compared with TNF blockers. Avoid OLUMIANT in patients at risk. Patients with symptoms of thrombosis should discontinue OLUMIANT and be promptly evaluated. [see Warnings and Precautions ( 5.5 )].

brand names

Olumiant

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=866e9f35-9035-4581-a4b1-75a621ab55cf

generic names

BARICITINIB

bd867ca4-faaf-4920-af55-ee0db99ab1bf

indications and usage exact

1 INDICATIONS AND USAGE OLUMIANT ® is a Janus kinase (JAK) inhibitor indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. ( 1.2 ) the treatment of adult patients with severe alopecia areata. ( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1.3 ) 1.1 Rheumatoid Arthritis OLUMIANT ® (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine. 1.2 Coronavirus Disease 2019 (COVID-19) OLUMIANT is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 1.3 Alopecia Areata OLUMIANT is indicated for the treatment of adult patients with severe alopecia areata. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.

indications and usage tables exact

is original packager

true

manufacturer names

Eli Lilly and Company

matched search terms

tumor

package ndcs

0002-4182-30
0002-4182-61
0002-4732-30
0002-4479-30
0002-4479-61

product ndcs

0002-4182
0002-4732
0002-4479

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Warnings and Precautions ( 5.8 ) 06/2026

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

2047241
2047247
2205472
2205474
2588561
2601725

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00600.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA207924

brand names

Olumiant

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 436
end exclusive: true
exact text: 1 INDICATIONS AND USAGE OLUMIANT ® is a Janus kinase (JAK) inhibitor indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) the tr
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 0

current approval status

not_reconciled

duplicate text group

dup-26592a6457302f8222e9

extraction review status

automated_candidate_pending_source_review

generic names

BARICITINIB

ind-span-db09e490fd87c76b92e8

label id

bd867ca4-faaf-4920-af55-ee0db99ab1bf

positive predicate support span

end: 78
end exclusive: true
exact text: is a Janus kinase (JAK) inhibitor indicated
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 35

qualifier mentions

context exact
anus kinase (JAK) inhibitor indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis who
kind
age
polarity
not_inferred
span
end
115
end exclusive
true
exact text
adult patients
label id
bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start
101

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 236
end exclusive: true
exact text: 1 INDICATIONS AND USAGE OLUMIANT ® is a Janus kinase (JAK) inhibitor indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers.
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bd867ca4-faaf-4920-af55-ee0db99ab1bf%22

spl effective date

2026-06-30

spl set id

866e9f35-9035-4581-a4b1-75a621ab55cf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · limitation of use

application numbers

NDA207924

brand names

Olumiant

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 621
end exclusive: true
exact text: a Janus kinase (JAK) inhibitor indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. ( 1.2 ) the treatment of adult patients with severe a
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 37

current approval status

not_reconciled

duplicate text group

dup-09e214baabb666c09eaa

extraction review status

automated_candidate_pending_source_review

generic names

BARICITINIB

ind-span-7772488fa329e819abc8

label id

bd867ca4-faaf-4920-af55-ee0db99ab1bf

positive predicate support span

Source null

qualifier mentions

context exact
( 1.1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
kind
regimen
polarity
not_inferred
span
end
420
end exclusive
true
exact text
in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine
label id
bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start
290

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 421
end exclusive: true
exact text: ( 1.1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 237

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bd867ca4-faaf-4920-af55-ee0db99ab1bf%22

spl effective date

2026-06-30

spl set id

866e9f35-9035-4581-a4b1-75a621ab55cf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 3 · unclassified context

application numbers

NDA207924

brand names

Olumiant

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 767
end exclusive: true
exact text: TNF blockers. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. ( 1.2 ) the treatment of adult patients with severe alopecia areata. ( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclospo
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 222

current approval status

not_reconciled

duplicate text group

dup-bbedf5e15840303d6441

extraction review status

automated_candidate_pending_source_review

generic names

BARICITINIB

ind-span-fd5a663aac661d364c98

label id

bd867ca4-faaf-4920-af55-ee0db99ab1bf

positive predicate support span

Source null

qualifier mentions

context exact
( 1.1 ) the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mec
kind
age
polarity
not_inferred
span
end
478
end exclusive
true
exact text
adults
label id
bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start
472

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 567
end exclusive: true
exact text: ( 1.1 ) the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO.
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 422

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bd867ca4-faaf-4920-af55-ee0db99ab1bf%22

spl effective date

2026-06-30

spl set id

866e9f35-9035-4581-a4b1-75a621ab55cf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA207924

brand names

Olumiant

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 836
end exclusive: true
exact text: nosuppressants such as azathioprine and cyclosporine. ( 1.1 ) the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. ( 1.2 ) the treatment of adult patients with severe alopecia areata. ( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1.3 ) 1.1 Rheumatoid Arthr
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 368

current approval status

not_reconciled

duplicate text group

dup-7e707a0cd6374d815b5d

extraction review status

automated_candidate_pending_source_review

generic names

BARICITINIB

ind-span-57dc10eff36e6520dc40

label id

bd867ca4-faaf-4920-af55-ee0db99ab1bf

positive predicate support span

Source null

qualifier mentions

context exact
( 1.2 ) the treatment of adult patients with severe alopecia areata.
kind
age
polarity
not_inferred
span
end
607
end exclusive
true
exact text
adult patients
label id
bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start
593

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 636
end exclusive: true
exact text: ( 1.2 ) the treatment of adult patients with severe alopecia areata.
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 568

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bd867ca4-faaf-4920-af55-ee0db99ab1bf%22

spl effective date

2026-06-30

spl set id

866e9f35-9035-4581-a4b1-75a621ab55cf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · limitation of use

application numbers

NDA207924

brand names

Olumiant

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1007
end exclusive: true
exact text: atment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. ( 1.2 ) the treatment of adult patients with severe alopecia areata. ( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1.3 ) 1.1 Rheumatoid Arthritis OLUMIANT ® (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 437

current approval status

not_reconciled

duplicate text group

dup-62027e5973c7498bfd0b

extraction review status

automated_candidate_pending_source_review

generic names

BARICITINIB

ind-span-10361f519921c639ec81

label id

bd867ca4-faaf-4920-af55-ee0db99ab1bf

positive predicate support span

Source null

qualifier mentions

context exact
( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
kind
regimen
polarity
not_inferred
span
end
806
end exclusive
true
exact text
in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants
label id
bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start
690

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 807
end exclusive: true
exact text: ( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 637

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bd867ca4-faaf-4920-af55-ee0db99ab1bf%22

spl effective date

2026-06-30

spl set id

866e9f35-9035-4581-a4b1-75a621ab55cf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 6 · unclassified context

application numbers

NDA207924

brand names

Olumiant

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1015
end exclusive: true
exact text: with severe alopecia areata. ( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1.3 ) 1.1 Rheumatoid Arthritis OLUMIANT ® (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one o
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 608

current approval status

not_reconciled

duplicate text group

dup-f2aa72658aa4d8927d2a

extraction review status

automated_candidate_pending_source_review

generic names

BARICITINIB

ind-span-6dc21ced35fbbea35c07

label id

bd867ca4-faaf-4920-af55-ee0db99ab1bf

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 815
end exclusive: true
exact text: ( 1.3 )
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 808

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bd867ca4-faaf-4920-af55-ee0db99ab1bf%22

spl effective date

2026-06-30

spl set id

866e9f35-9035-4581-a4b1-75a621ab55cf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · positive indication candidate

application numbers

NDA207924

brand names

Olumiant

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1259
end exclusive: true
exact text: ere alopecia areata. ( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1.3 ) 1.1 Rheumatoid Arthritis OLUMIANT ® (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 616

current approval status

not_reconciled

duplicate text group

dup-8a709cd82ce0695a636f

extraction review status

automated_candidate_pending_source_review

generic names

BARICITINIB

ind-span-605fce3825c6cd84f199

label id

bd867ca4-faaf-4920-af55-ee0db99ab1bf

positive predicate support span

end: 878
end exclusive: true
exact text: is indicated
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 866

qualifier mentions

context exact
OLUMIANT ® (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who
kind
age
polarity
not_inferred
span
end
914
end exclusive
true
exact text
adult patients
label id
bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start
900

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1059
end exclusive: true
exact text: 1.1 Rheumatoid Arthritis OLUMIANT ® (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers.
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 816

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bd867ca4-faaf-4920-af55-ee0db99ab1bf%22

spl effective date

2026-06-30

spl set id

866e9f35-9035-4581-a4b1-75a621ab55cf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 8 · limitation of use

application numbers

NDA207924

brand names

Olumiant

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1476
end exclusive: true
exact text: inib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine. 1.2 Coronavirus Disease 2019 (COVID-19) OLUMIANT is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive m
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 860

current approval status

not_reconciled

duplicate text group

dup-10859dd632d1dda84554

extraction review status

automated_candidate_pending_source_review

generic names

BARICITINIB

ind-span-22c5e66709c1ccfa45fa

label id

bd867ca4-faaf-4920-af55-ee0db99ab1bf

positive predicate support span

Source null

qualifier mentions

context exact
Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.
kind
regimen
polarity
not_inferred
span
end
1275
end exclusive
true
exact text
in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine
label id
bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start
1105

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1276
end exclusive: true
exact text: Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 1060

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bd867ca4-faaf-4920-af55-ee0db99ab1bf%22

spl effective date

2026-06-30

spl set id

866e9f35-9035-4581-a4b1-75a621ab55cf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 9 · positive indication candidate

application numbers

NDA207924

brand names

Olumiant

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1745
end exclusive: true
exact text: e : Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine. 1.2 Coronavirus Disease 2019 (COVID-19) OLUMIANT is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 1.3 Alopecia Areata OLUMIANT is indicated for the treatment of adult patients with severe alopecia areata. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biolo
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 1077

current approval status

not_reconciled

duplicate text group

dup-660e5a1dfeb58453cdf3

extraction review status

automated_candidate_pending_source_review

generic names

BARICITINIB

ind-span-2cf60ebb20c2603d6622

label id

bd867ca4-faaf-4920-af55-ee0db99ab1bf

positive predicate support span

end: 1338
end exclusive: true
exact text: is indicated
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 1326

qualifier mentions

context exact
ment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mec
kind
age
polarity
not_inferred
span
end
1418
end exclusive
true
exact text
adults
label id
bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start
1412

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1545
end exclusive: true
exact text: 1.2 Coronavirus Disease 2019 (COVID-19) OLUMIANT is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 1277

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bd867ca4-faaf-4920-af55-ee0db99ab1bf%22

spl effective date

2026-06-30

spl set id

866e9f35-9035-4581-a4b1-75a621ab55cf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 10 · positive indication candidate

application numbers

NDA207924

brand names

Olumiant

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1815
end exclusive: true
exact text: treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 1.3 Alopecia Areata OLUMIANT is indicated for the treatment of adult patients with severe alopecia areata. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 1346

current approval status

not_reconciled

duplicate text group

dup-c53081bfb3637dde6e6e

extraction review status

automated_candidate_pending_source_review

generic names

BARICITINIB

ind-span-058dcb1f7897769828cb

label id

bd867ca4-faaf-4920-af55-ee0db99ab1bf

positive predicate support span

end: 1587
end exclusive: true
exact text: is indicated
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 1575

qualifier mentions

context exact
Alopecia Areata OLUMIANT is indicated for the treatment of adult patients with severe alopecia areata.
kind
age
polarity
not_inferred
span
end
1623
end exclusive
true
exact text
adult patients
label id
bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start
1609

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1652
end exclusive: true
exact text: 1.3 Alopecia Areata OLUMIANT is indicated for the treatment of adult patients with severe alopecia areata.
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 1546

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bd867ca4-faaf-4920-af55-ee0db99ab1bf%22

spl effective date

2026-06-30

spl set id

866e9f35-9035-4581-a4b1-75a621ab55cf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 11 · limitation of use

application numbers

NDA207924

brand names

Olumiant

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1815
end exclusive: true
exact text: -invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 1.3 Alopecia Areata OLUMIANT is indicated for the treatment of adult patients with severe alopecia areata. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 1453

current approval status

not_reconciled

duplicate text group

dup-1bb29a6aca25cf9321bb

extraction review status

automated_candidate_pending_source_review

generic names

BARICITINIB

ind-span-8e68701602e87b86c5d6

label id

bd867ca4-faaf-4920-af55-ee0db99ab1bf

positive predicate support span

Source null

qualifier mentions

context exact
Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
kind
regimen
polarity
not_inferred
span
end
1814
end exclusive
true
exact text
in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants
label id
bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start
1698

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1815
end exclusive: true
exact text: Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
label id: bd867ca4-faaf-4920-af55-ee0db99ab1bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 078e0117b0932f976a5144055d8333e3cab0f96510281bf58d23c9d96241a3b0
start: 1653

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bd867ca4-faaf-4920-af55-ee0db99ab1bf%22

spl effective date

2026-06-30

spl set id

866e9f35-9035-4581-a4b1-75a621ab55cf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Preserved source evidence · Not medical advice